Waters introduces the new Waters BioAccord system to support biopharmaceutical attribute monitoring

Introduction: This integrated high-resolution LC-MS system combines the Waters BioAccord system with the ACQUITY Premier UPLC system, which utilizes the groundbreaking MaxPeak High Performance Surface (HPS) technology. Waters Corporation (NYSE: WAT) recently launched the Waters BioAccord System with ACQUITY Premier ultra-performance liquid chromatography, an integrated high-resolution LC-MS system that combines the Waters BioAccord system with the ACQUITY Premier UPLC system using the groundbreaking MaxPeak High Performance Surface (HPS) technology. This improves analyte recovery and batch-to-batch reproducibility, simplifying multi-attribute monitoring of biotherapeutics and helping regulated laboratories accelerate the process of bringing drugs to patients. Dr. Udit Batra, President and CEO of Waters Corporation, said: "While next-generation biotherapeutics hold immense promise, characterizing them can be challenging if they contain low levels of analytes. This is because these analytes interact strongly with the metal surfaces inside traditional LC instruments, binding to them and making them almost undetectable. For biopharmaceutical analysis, information is wealth. The BioAccord system with ACQUITY Premier solves the problem of analyte interaction with metal surfaces, allowing scientists to uncover all the information in the sample faster, from the first injection. " The BioAccord system with ACQUITY Premier is a compact benchtop instrument that uses MaxPeak HPS technology and the ACQUITY RDa mass spectrometer detector powered by SmartMS. Regardless of the analyst's skill level, it allows for easy monitoring of critical quality attributes of biotherapeutics and assessment of their manufacturing processes while reducing risk. This is thanks to the system's regulatory-compliant data acquisition and workflows, ensuring consistent data quality across users and systems. MaxPeak HPS technology is an organic/inorganic hybrid surface technology that creates a barrier between the sample and the biocompatible metal surfaces of the UPLC inlet and column. By reducing or eliminating non-specific adsorption, MaxPeak HPS technology offers several advantages, including: · Up to 300% increase in detector sensitivity, allowing for more accurate analysis of free oligosaccharides, which is critical for monitoring biopharmaceutical manufacturing processes and product quality [1] · Significantly improved analyte recovery and method sensitivity, enabling the determination of modified peptides and impurities that cannot be detected by conventional methods · Sharper peaks and higher peak capacity, effectively improving the accuracy of analyte identification and data interpretation · Higher reproducibility for separations prone to adsorption losses, reducing rework or failures and improving result reliability · Eliminates the need for system passivation, saving valuable samples and shortening instrument run times · Analytical methods can be easily transferred between different locations and companies The BioAccord system with ACQUITY Premier is easy to deploy thanks to automated setup and workflows powered by SmartMS technology. It provides system and application training and pre-configured biopharmaceutical analytical methods for each key workflow to ensure rapid system deployment. In addition, given the importance of compliance and data integrity to many biopharmaceutical laboratories, the system is built on the waters_connect informatics platform, with industry-leading compliant informatics architecture and globally accessible professional validation services. The BioAccord system with ACQUITY Premier is expected to be available to customers from the end of September. Other References Learn more: BioAccord system with ACQUITY Premier Read the blog post: "Some technologies work better together: BioAccord system with ACQUITY Premier" About Waters Corporation (www.waters.com) Waters Corporation (NYSE: WAT) is a leading global provider of advanced analytical instruments. As a pioneer in chromatography, mass spectrometry, and thermal analysis innovation technologies, Waters has served the life sciences, materials sciences, and food sciences industries for over 60 years. Waters operates directly in 35 countries and regions, with 14 manufacturing facilities and over 7,400 employees, selling its products to over 100 countries and regions. About Waters China Since entering China in the 1980s, Waters has grown significantly in size and strength, with operating centers in mainland China, Hong Kong, and Taiwan, employing more than 600 local employees and establishing laboratories and training centers in Shanghai, Beijing, Guangzhou, and Chengdu. Since the establishment of Waters Technology (Shanghai) Co., Ltd. in 2003, China has become Waters' second largest market globally, second only to the United States. As a partner to analytical scientists, Waters has always been committed to improving local technical capabilities, supporting the cultivation of local technical talent, and promoting the establishment and improvement of relevant industry standards and regulations in the pharmaceutical, food safety, health science, and environmental protection industries. With outstanding talent and global presence, Waters has created significant value for its business partners and is committed to meeting the needs of Chinese consumers for a better life. For related instruments and technologies, please click on the special session: #Liquid Chromatography (LC)# Bio-mass spectrometry/MALDI-TOF [Source: Instrument Information Network] Unauthorized reproduction is prohibited. Tags: Waters Technology Ultra-performance Liquid Chromatography

Copyright belongs to the author.
For commercial reprints, please contact the author for authorization; for non-commercial reprints, please indicate the source.
Link: https://www.instrument.com.cn/news/20210915/591609.shtml
Source: Instrument Information Network